News Sanofi signs $1.9bn deal to buy Dren Bio autoimmune drug Sanofi buys a drug from Dren Bio to claim a stake in the emerging field of deep B-cell depletion for autoimmune diseases.
News Can Dupixent plug treatment gap in bullous pemphigoid? The FDA is scheduled to deliver a verdict on Sanofi and Regeneron's Dupixent for rare autoimmune skin disorder bullous pemphigoid in June.
News First biosimilar fast-acting insulin reaches US market Sanofi has claimed FDA approval for the first biosimilar of Novo Nordisk's rapid-acting insulin analogue Novolog.
News Sanofi, J&J abandon trial of E coli vaccine after poor data Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by E coli looks all but defunct after they abandon a phase 3 trial.
News Could OTC Cialis for erectile dysfunction reach the US? Sanofi's consumer healthcare unit Opella could finally be able to bring an OTC PDE-5 inhibitor for erectile dysfunction to the US market.
News 11 blockbuster drugs to look out for in 2025 Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
